



New Bacteriophages Members of the *Ackermannviridae* Family Specific for *Klebsiella pneumoniae* ST258

Estefanía Tisalema-Guanopatin, BSc,^{1,2} Fausto Cabezas-Mera, MSc,³ Karla Nolivos-Rodríguez, BSc,¹ Isabel Fierro, MSc,¹ Lourdes Pazmiño, MPH,¹ Daniel Garzon-Chavez, PhD,⁴ Alexis Debut, PhD,⁵ Karla Vizuete, MSc,⁵ and Jorge Aníbal Reyes, PhD^{1,6,*}

Abstract

Background: Carbapenem-resistant *Klebsiella pneumoniae*, particularly isolates classified as sequence-type 258 (ST258), are multidrug-resistant strains that are strongly associated with poor-prognosis nosocomial infections, as current therapeutic options are limited and ineffective. In recent years, phage therapy has emerged as a promising treatment option for these scenarios.

Methodology and Results: We report the isolation and characterization of three new phages against *Klebsiella pneumoniae* ST258 strains recovered from Machángara river wastewater. These new members of the *Ackermannviridae* family showed stability over a wide temperature and pH range and burst sizes ranging from 6 to 44 plaque-forming units per bacteria. Their genomes were about 157 kilobases, with an average guanine-cytosine content of 46.4% and showed presence of several transfer RNAs, which also allowed us to predict *in silico* a lytic replicative cycle due to the presence of endolysins and lysozymes.

Conclusion: Three lytic phages of *Ackermannviridae* family were recovered against *Klebsiella pneumoniae* ST258 strains from sewage; however, further characterization is needed for future consideration as therapeutic alternatives.

Keywords: *Ackermannviridae*, *Klebsiella pneumoniae*, ST258, wastewater, tRNA, lytic

Introduction

THE OVERUSE OF ANTIBIOTICS has led to rapid spread of multidrug-resistant (MDR) *Klebsiella pneumoniae* virulent lineages, which are associated with high mortality rates especially in infections by isolates belonging to clonal complex 258, where isolates with sequence-type 258 (ST258) are considered as an “high-risk” clonal group causing a large proportion of infections, associated with worse prognosis.^{1–6} Among the alternative treatments proposed to address this public health crisis, bacteriophage (phage) therapy has

demonstrated efficacy in experimental animal models and shows promise in clinical cases involving MDR pathogen infections, including ST258 strains.^{7–10}

Moreover, the most common sources of isolation are relatively easy to access, such as sewage and hospital wastewater.^{11–14} For example, a recent study published by Hesse et al.⁸ evaluated the efficacy of early treatment with two phages, termed P1 and P2, in reducing bacterial load in infected mice with refractory bacteremia. The results of the study showed that early treatment with both phages, either individually or in combination, resulted in a significant

¹Facultad de Ciencias Químicas, Universidad Central del Ecuador (UCE), Ciudadela Universitaria Avenida América, Quito, Pichincha, Ecuador.

²Faculty of Engineering and Applied Sciences, Universidad Internacional SEK, Quito, Ecuador.

³Instituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales (COCIBA), Universidad San Francisco de Quito (USFQ), Diego de Robles y Vía Interoceánica, Quito, Ecuador.

⁴Universidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud (COCSA), Diego de Robles y Vía Interoceánica, Quito, Ecuador.

⁵Centro de Nanociencia y Nanotecnología (CENCINAT), Universidad de las Fuerzas Armadas ESPE, Sangolquí, Ecuador.

⁶Departamento de Microbiología, Hospital del IESS Quito Sur, Avenida Moraspungo, Quito, Ecuador.

reduction in bacterial load compared with placebo-treated animals. In addition, an improvement in survival was observed in mice treated with the phages compared with controls.⁸

Despite some promising results with other high-risk clonal lineages such as ST11, ST15, and ST16, currently available evidence remains insufficient for consideration beyond experimental treatments. Considering the current challenge posed by MDR lineages of *K. pneumoniae*, this study aims to address the knowledge gap by *in vitro* characterization of phages recovered from wastewater and evaluation of their lytic potential on ST258 strains for future development of effective therapeutic strategies.

Materials and Methods

Host strains, sample collection and isolation, enrichment, titration, and purification

Two clinical strains of *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Klebsiella pneumoniae* ST258 (14-765 and 14-751) donated by the Instituto Nacional de Investigación en Salud Pública–Leopoldo Izquieta Pérez (INSPI-LIP) from Ecuador were used as host bacteria. The results of antimicrobial susceptibility testing are in Supplementary Table S1. To obtain the exponential phase, 500 μ L of a saturated broth (obtained from one or two isolated MacConkey agar colonies mixed in 4.5 mL of Tryptic Soy Broth [TSB] at 37°C and constant shaking at 9 \times g overnight) was used beforehand. Next, 500 μ L of the aforementioned mixture was added to 4.5 mL of TSB and incubated for 4 h at 180 rpm. A standard inoculum of 0.5 McFarland (1.5×10^8 CFU/mL) was used for all assays.

Samples of wastewater were collected from two different points of Machángara river, Quito-Ecuador. Sample named K0601 was collected from point one, coordinates: 0°12'34.7" S 78°28'36.6" W and Sample T0701 from collection point two, coordinates: 0°16'37" S 78°31'14" W, all samples were stored at 4°C for 24 h for sedimentation.

Bacteriophage isolation was performed according to the protocol described by Kropinski et al.¹⁵ and Clokie and Kropinski¹⁶ with certain modifications. In brief, 1 mL of the host strain in exponential phase culture, 49 mL of doubly concentrated TSB supplemented with 10 mM Ca²⁺ and Mg²⁺, and 50 mL of supernatant, previously filtered with filter paper (10 μ m pore size filter) to separate the suspended solids present in the wastewater samples, were mixed. The mixture was incubated for 24 h at 37°C. The mixture was centrifuged at 1475 \times g for 10 min to remove cells, and the supernatant was then filtered through a 0.22 μ m pore size filter and stored at 4°C.

Phage presence was verified using the spot test, for which 50 μ L of the filtered supernatant was dropped onto the host strain inoculated by extension on Tryptic Soy Agar supplemented with 10 mM Ca²⁺ (TSAd10) and incubated overnight.

For phage isolation, the double layer agar (DLA) technique was used using nutrient agar supplemented with 10 mM Ca²⁺. Serial dilutions and the DLA technique were performed with the previously filtered supernatant. In brief, 100 μ L of exponential phase culture, 100 μ L of dilution, and 5 mL of agar (top layer) were mixed and poured over the base layer and incubated. Procedure was repeated with all serial dilutions. Phage concentration was expressed in plaque-forming units

per milliliter (PFU/mL). We selected potential phages with concentrations over 1×10^{10} PFU/mL.

For purification, a lysis plaque (10^5 – 10^8 PFU/mL) was taken, resuspended in 900 μ L of buffer (MgSO₄•7H₂O 8 mM, Tris-HCl 50 mM, pH 8.4) and shaken vigorously to dislodge the phage from the agar. The mixture was inoculated by extension on TSAd10 and left to stand for 30 min. Later, 500 μ L of exponential phase culture was mixed with 5 mL of TSAd10 on top of the aforementioned agar and incubated for 20 h. The best defined and spaced plaques formed after 20 h were picked and stored at 4°C in 1 mL of buffer and 10 μ L of chloroform for preservation.

In vitro phage activity and stability

Phage characterization was performed by the method described by Manohar et al.¹⁷ Thus, 100 μ L of exponential phase culture host bacteria and 100 μ L of purified phage was mixed and incubated for 25 min. After centrifugation, the pellet was homogenized using 10 mL of TSB, the DLA technique was performed to obtain the number of phages. Burst size was calculated dividing the final number of free phages by the initial number of phages. For pH stability assay we added 100 μ L of purified phage in 900 μ L of saline solution adjusted to different pH and incubated for 4 h, whereas for thermostability assay a volume of 100 μ L of purified phage was maintained at different temperatures for 1 h.

All assays were performed in triplicate and the DLA technique was applied. Adsorption rate was performed according to reference.¹⁸ In brief, 100 μ L of the exponential phase host strain was mixed with 100 μ L of purified phage, allowed to stand for 5 min at room temperature, 100 μ L of this mixture was added in 9.9 mL of TSB and incubated for 1 h, every 10 min the DLA method was performed. Adsorption constant was calculated with the following equation:¹⁵ $K = \frac{2.3}{B \cdot t} \log \frac{P_0}{P}$, where B is the initial concentration of bacteria, P_0 the initial titer, P the final titer, and t the time interval between P_0 and P . The constant was expressed in mL/min.

Genomic DNA extraction

The phage was suspended in buffer, concentrated by centrifugation and filtered through a 0.22 μ m pore-size filter. DNA extraction was performed using Wizard Promega protocol and was modified by adding proteinase K and DNase I. 1 mL of concentrated phage was mixed with 10 μ L of DNase I, 1 μ L of RNase A, 500 μ L of lysis solution and 4 μ L of proteinase K, shaken and incubated at the following temperatures: 55°C (60 min), 65°C (15 min), then 320 μ L isopropanol was added. Six hundred fifty microliters of the mixture was transferred to a spin column and centrifuged (1 min at 6000 g). Wash solution (90% ethanol) was added 400 μ L and centrifuged again. Finally, we added 75 μ L of rehydration buffer to the column, centrifuged again and obtained phage genomic DNA, which was stored at –20°C.

Complete genome sequencing and analysis

Sequencing was performed by Biosequence (Ecuador) in the Illumina MiSeq system. Raw sequencing data were deposited in the Sequence Reads Archive: BioProject: PRJNA815380, BioSamples: SAMN26549669 (K751), SAMN26549667 (T751), and SAMN26549668 (T765). Reads obtained were

assembled *de novo* using Unicycler¹⁹ in PATRIC²⁰. Quality and integrity of the viral metagenome-assembled genomes were evaluated with CheckV²¹ and subsequently annotated with Prokka²² in Galaxy.²³

Genomes were aligned and rearranged with MAUVE.²⁴ Prokaryotic virulence, toxin encoding, and antimicrobial resistance genes were searched for using Bakta.²⁵ Our genomes recovered were deposited in GenBank: ON202820 (K751), ON323462 (T751), and ON399185 (T765). Taxonomic assignment was performed by KRAKEN2²⁶ and average nucleotide identity (ANI) was calculated to support it.²⁷ The phylogenomic tree of the whole-genome sequences were generated by VICTOR.²⁸ The replicative cycle was predicted *in silico* with BACPHLP²⁹ and PhageAI.³⁰

Results

Phenotypic profile

Phages presence was evidenced by formation of lysis zones and plaques of variable size (ϕ 1.5–2.0 mm) with a translucent center and a surrounding halo (Supplementary Figs. S1 and S2). Three possible phages were isolated and named according to the recommendations of the International Committee on Taxonomy of Viruses:³¹ (Table 1) *Klebsiella_virus_K751* (K751), *Klebsiella_virus_T751* (T751) and *Klebsiella_virus_T765* (T765). T751 and T765 were inactivated at temperatures $>60^{\circ}\text{C}$, whereas K751 was completely inactivated at 80°C (Supplementary Fig. S3).

Regarding pH, the candidates survive in an environment of pH 4–11, and are completely inactivated at pH 12. K751 and T765 tolerated pH 3 (Supplementary Fig. S4). K751 and T751 reported a latency period of ~ 35 min, whereas T765 was 45 min. Burst sizes (PFU/bacterial) were 6, 44, and 10, respectively (Fig. 1). In addition, at 10 min, it was estimated that 28.4% of K751, 12.1% of T751 and 24.4% of T765 viral particles were adsorbed on the host cell (Table 1).

Genomic profile

Each recovered genome was characterized as double-stranded linear DNA of ~ 157 kpb, $>94\%$ complete and an average guanine-cytosine (GC) content of 46.4%. The *in silico* predicted replicative cycle for all three candidates was lytic (Table 1). A multiple alignment of the rearranged genomes showed that the phages shared three syntenic collinear blocks (homologous regions) (Fig. 2), complemented by values $>90\%$ of ANI. This allowed us to deduce that our three phages are within the same species. About 190 open reading frames and 200 coding DNA sequences were annotated in each genome. Of the latter, $>87\%$ are hypothetical proteins.

Five common transfer RNAs (tRNAs; tRNA^{Thr}, tRNA^{Met}, tRNA^{Trp}, tRNA^{Tyr}, and tRNA^{Gln}), and one additional (tRNA^{Asn}) in T751 y T765. One small RNA (STnc100) was found in all three genomes. Prokaryotic virulence, toxin-encoding, and antimicrobial resistance genes were not present, demonstrating the absence of risk of transfer by lysogenization

TABLE 1. CHARACTERISTICS OF PHAGE ISOLATED AGAINST CARBAPENEM-RESISTANT *KLEBSIELLA PNEUMONIAE* ST258 STRAINS

	K751	T765	T751
Host strain	14-751	14-765	14-751
Maximum concentration (PFU/mL)	1.0×10^{11}	9.0×10^{11}	2.0×10^{10}
Phenotypic profile			
Temperature ($^{\circ}\text{C}$)	-16 to 70	-16 to 60	-16 to 60
pH	3 to 11	3 to 11	4 to 11
Adsorption constant, K (mL/min)	2.1×10^{-10}	5.1×10^{-10}	1.1×10^{-10}
Adsorption at 10 min (%)	28.4	24.4	12.1
Burst size (PFU/bacterial)	6	10	44
Latent period (minutes)	35	45	35
Taxonomy			
Family	<i>Ackermannviridae</i>	<i>Ackermannviridae</i>	<i>Ackermannviridae</i>
Genus	<i>Taipeivirus</i>	<i>Taipeivirus</i>	<i>Taipeivirus</i>
Genomic profile			
Size (bp)	157.100	157.384	157.384
Depth	$125.1 \times$	$219.2 \times$	$274.7 \times$
Content GC (%)	46.5	46.4	46.4
Integrity (%)	94.9	94.9	94.8
ORF	197	195	196
CDS	204	205	204
Hypothetical proteins	188	188	190
Functional proteins	23	24	21
tRNA	5	6	6
sRNA	1	1	1
<i>In silico</i> replicative cycle (%)			
PhageAI (lytic)	93.45	93.05	93.05
BachliB (lytic)	97.02	97.02	97.02

CDS, coding DNA sequences; GC, guanine-cytosine content; ORFs, open reading frames; PFU, plaque-forming units; sRNA, small RNA; tRNA, transfer RNA.




FIG. 1. Kinetics of *Klebsiella_virus_K751*, *Klebsiella_virus_T751*, and *Klebsiella_virus_T765*. The relationship between concentration and incubation time with their host cell is shown. Results are based on three replicates. PFU, plaque-forming units.

or phage-mediated transduction³² (Fig. 3; Supplementary Fig. S5). K751, T765, and T751 clustered with members of the genus *Taipeivirus* (Fig. 4), as preliminarily expected, as >90% of the raw reads were taxonomically classified within it.

Discussion

The emergence of carbapenem-resistant *Klebsiella pneumoniae* ST258 strains has led to strong therapeutic challenges for which some alternatives have been proposed. Among these alternatives is phage therapy, however, for many of these potential candidates, the minimum necessary information is not available or is still in the experimental stage. In the context of our research, we isolated three new lytic phages belonging to the family *Ackermannviridae* that showed significant genetic similarities despite different times and geographical origins.

Our results indicated that our phages belong to the same species. Reports of phages isolated from wastewater against ST258 strains^{7,8,12–14,33} have already shown that there is no exclusivity for a single family or taxonomic group.^{30,34,35} Despite the varied phylogenomic distance between families, mostly aquatic environments shared with their host,^{36–38} such

as wastewater, which due to the presence of human, animal, and hospital waste, are a source rich and varied of these micro-organisms.^{39–41}

After phenotypic analysis and considering the aforementioned, high stability under different temperature and pH conditions, and a latency period ranging from 10 to 40 min were expected.^{14,42–44} Short latency periods and large burst sizes are usually a combination that increases therapeutic potential; however, our values show a discrete difference, which could indicate that phage-host dynamics are being affected possibly due to the inherent facility of *K. pneumoniae* to generate spontaneous phage-resistant mutants.^{32,34,45–48}

The presence of these mutants increases bacterial density and affects the adsorption rate^{49–51} due to poor receptor recognition^{47,48,52} resulting in slow adhesion and poor initial diffusion,⁵³ in agreement with our report, in which <30% of free phages were adsorbed in the first 10 min, in contrast to Zurabov and Zhilenkov, who recommend that for the selection of therapeutic phages they should adsorb between 70% and 80% in the same period.^{14,44,54} We describe phages of genus *Taipeivirus* belong to *Ackermannviridae* family with lytic activity in KPC-producing *K. pneumoniae*.

After genomic analysis, the mean GC content (46.4%) of our phages was lower than expected for *Klebsiella* (57.5%),




FIG. 2. Progressive multiple alignment performed with MAUVE to compare *Klebsiella_virus_K751*, *Klebsiella_virus_T751*, and *Klebsiella_virus_T765*. Each genome is arranged horizontally with homologous segments (locally collinear blocks) delineated as colored rectangles. Regions inverted with respect to the first genome taken as reference are placed below those that match in forward orientation.




FIG. 3. Genomic map of *Klebsiella_virus_K751*. CDS are colored according to their function such as morphogenesis (purple), replication (green), recombination and repair (pink), lysis (light green), tRNA (blue), and other functions (orange). CDS, coding DNA sequences; tRNA, transfer RNA.




FIG. 4. Phylogenomic tree generated by VICTOR using the complete genome sequences of *Klebsiella_phage_T751*, *Klebsiella_phage_T765*, *Klebsiella_phage_K751* and members of the nearest *Ackermannviridae* according to BLASTn. Members of the families *Drexelviriidae* and *Autographiviridae* were used as outgroups.

so it could infect other gram-negative bacteria, as previous studies corroborate that genomic GC content accurately predicts (>95%) potential hosts at the phylum level, but not at lower taxonomic levels.^{52,55,56} A marked organization of structural and functional genes was evident in each genome, in addition, genes encoding tail proteins (*gp5*, *gp3*, and *gp17*), required for capsid penetration, adsorption,⁵⁷ and irreversible binding to their receptors,⁵⁸⁻⁶⁰ which have been extensively studied in common models such as enterobacteriophage T4 were also found.⁶¹

Furthermore, five similar and one additional tRNA were present in T751 and T765, which is in agreement with Bailly-Bechet et al. and Maganha de Almeida Kumlien et al.⁶² who state that a lytic phage contains an average of 4 tRNAs and even more, which are useful to compensate the genomic

compositional differences with the host, and consequently achieve a more robust integration.⁶¹⁻⁶³ The presence of tRNAs is possibly unique to lytic phages, as they have not been described in lysogenic phages. The tRNAs present correspond to codons abundant in the phage and probably rare in the host, which gives them an advantage over their competitors by translating their proteins more efficiently, reducing latency time and increasing the burst size.⁶⁴⁻⁶⁶ In addition, GC content and tRNAs could indicate the closeness between phage and host, although this relationship has not been explored in detail.⁶⁶

Despite reporting encouraging results, phenotypic analysis of our phages revealed certain issues that limit their use as therapeutics and need to be further addressed before proposing them for *in vivo* or clinical trials.

Conclusion

Three lytic phages of the *Ackermannviridae* family were recovered against *Klebsiella pneumoniae* ST258 strains from sewage; however, further characterization is needed for future consideration as therapeutic alternatives. Furthermore, our findings support the strategic targeting of phages for infections by MDR pathogens.

Acknowledgments

The authors are grateful to the Dirección de Investigación de Universidad Central del Ecuador (UCE), Instituto de Investigación y Zoonosis (CIZ), Centro de Nanociencia y Nanotecnología (CENCINAT) of Universidad de las Fuerzas Armadas ESPE, and Instituto de Microbiología of Universidad San Francisco de Quito (IMUSFQ).

Authors' Contributions

J.A.R. and F.C.M. were responsible for conceptualization. E.T.G. and K.N.R. designed and carried out the methodology, formal analysis, validation, visualization, and research. TEM protocol and observation by K.V. and A.D. The writing—original draft preparation was elaborated by E.T.G. The writing—review and editing article were realized by E.T.G., F.C.M., K.N.R., J.A.R., and L.P. Supervision, project administration, and funding acquisition were conducted by J.A.R., L.P., and I.F. All authors have read and agreed to the published version of the article.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

This study is supported by Call for proposals for senior research projects 2019 from Universidad Central del Ecuador, under the Project ID: DI-CONV-2019-052 titled in Spanish: “Alternativa a los antimicrobianos: aislamiento de bacteriófagos a partir de aguas residuales y aplicaciones en el sector salud e industria de alimentos.”

Supplementary Material

Supplementary Figure S1
Supplementary Figure S2
Supplementary Figure S3
Supplementary Figure S4
Supplementary Figure S5
Supplementary Table S1

References

- Andrey DO, Dantas PP, Martins WBS, et al. An emerging clone, *Klebsiella pneumoniae* carbapenemase 2-producing *K. pneumoniae* sequence type 16, associated with high mortality rates in a CC258-endemic setting. *Clin Infect Dis* 2020;71(7):E141–E150; doi: 10.1093/CID/CIZ1095
- Marsh JW, Mustapha MM, Griffith MP, et al. Evolution of outbreak-causing carbapenem-resistant *Klebsiella pneumoniae* ST258 at a tertiary care hospital over 8 years. *mBio* 2019;10(5):e01945-19; doi: 10.1128/MBIO.01945-19
- Ebomah KE, Okoh AI. An African perspective on the prevalence, fate and effects of carbapenem resistance genes in hospital effluents and wastewater treatment plant (WWTP) final effluents: A critical review. *Heliyon* 2020; 6(5):e03899; doi: 10.1016/J.HELIYON.2020.E03899
- Micozzi A, Gentile G, Santilli S, et al. Reduced mortality from KPC-*K. pneumoniae* bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-*K. pneumoniae*. *BMC Infect Dis* 2021;21(1):1–9; doi: 10.1186/S12879-021-06747-8/TABLES/5
- Protonotariou E, Meletis G, Pilalas D, et al. Polyclonal endemicity of carbapenemase-producing *Klebsiella pneumoniae* in ICUs of a Greek Tertiary Care Hospital. *Antibiotics* 2022;11(2):149; doi: 10.3390/ANTIBIOTICS 11020149
- Reyes J, Cárdenas P, Tamayo R, et al. Characterization of blaKPC-2-Harboring *Klebsiella pneumoniae* isolates and mobile genetic elements from outbreaks in a Hospital in Ecuador. *Microb Drug Resist* 2021;27(6):752–759; doi: 10.1089/MDR.2019.0433
- Thiry D, Passet V, Danis-Wlodarczyk K, et al. New bacteriophages against emerging lineages ST23 and ST258 of *Klebsiella pneumoniae* and efficacy assessment in *Galleria mellonella* Larvae. *Viruses* 2019;11(5):411; doi: 10.3390/V11050411
- Hesse S, Malachowa N, Porter AR, et al. Bacteriophage treatment rescues mice infected with multidrug-resistant *Klebsiella pneumoniae* ST258. *mBio* 2021;12(1):1–11; doi: 10.1128/MBIO.00034-21
- Liu JY, Lin TL, Chiu CY, et al. Decolonization of carbapenem-resistant *Klebsiella pneumoniae* from the intestinal microbiota of model mice by phages targeting two surface structures. *Front Microbiol* 2022;13:3110; doi: 10.3389/FMICB.2022.877074
- Anand T, Virmani N, Kumar S, et al. Phage therapy for treatment of virulent *Klebsiella pneumoniae* infection in a mouse model. *J Glob Antimicrob Resist* 2020;21:34–41; doi: 10.1016/J.JGAR.2019.09.018
- Balcão VM, Moreli FC, Silva EC, et al. Isolation and molecular characterization of a novel lytic bacteriophage that inactivates MDR *Klebsiella pneumoniae* strains. *Pharmaceutics* 2022;14(7):1412; doi: 10.3390/PHARMACEUTICS14071421
- D'Andrea MM, Marmo P, Henrici De Angelis L, et al. ϕ bO1E, a newly discovered lytic bacteriophage targeting carbapenemase-producing *Klebsiella pneumoniae* of the pandemic Clonal Group 258 clade II lineage. *Sci Rep* 2017; 7(1):2614; doi: 10.1038/s41598-017-02788-9
- Martins WMBS, Cino J, Lenzi MH, et al. Diversity of lytic bacteriophages against XDR *Klebsiella pneumoniae* sequence type 16 recovered from sewage samples in different parts of the world. *Sci Total Environ* 2022;839:156074; doi: 10.1016/J.SCITOTENV.2022.156074
- Hesse S, Rajaure M, Wall E, et al. Phage resistance in multidrug-resistant *Klebsiella pneumoniae* st258 evolves via diverse mutations that culminate in impaired adsorption. *mBio* 2020;11(1):e02530-19; doi: 10.1128/mBio.02530-19
- Kropinski AM, Mazzocco A, Waddell TE, et al. Enumeration of bacteriophages by double agar overlay plaque assay. *Methods Mol Biol* 2009;501:69–76; doi: 10.1007/978-1-60327-164-6_7
- Clokier MRJ, Kropinski AM. *Bacteriophages: Methods and Protocols, Volume 1: Isolation, Characterization and In-*

- teractions. 2009:68–74; Humana Press, a part of Springer Science+Business Media. doi: 10.1007/978-1-60327-164-67
17. Manohar P, Nachimuthu R, Lopes BS. The therapeutic potential of bacteriophages targeting gram-negative bacteria using *Galleria mellonella* infection model. *BMC Microbiol* 2018;18(1):97; doi: 10.1186/s12866-018-1234-4
 18. Rahaman M, Rahman M, Rahman M, et al. Poultry salmonella specific bacteriophage isolation and characterization. *Bangladesh J Vet Med* 2014;12(2):107–114; doi: 10.3329/BJVM.V12I2.21264
 19. Wick RR, Judd LM, Gorrie CL, et al. Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput Biol* 2017;13(6):e1005595; doi: 10.1371/JOURNAL.PCBI.1005595
 20. Parrello B, Butler R, Chlenski P, et al. A machine learning-based service for estimating quality of genomes using PATRIC. *BMC Bioinformatics* 2019;20(1):1–9; doi: 10.1186/S12859-019-3068-Y
 21. Nayfach S, Camargo AP, Schulz F, et al. CheckV assesses the quality and completeness of metagenome-assembled viral genomes. *Nat Biotechnol* 2020;39(5):578–585; doi: 10.1038/s41587-020-00774-7
 22. Seemann T. Prokka: Rapid prokaryotic genome annotation. *Bioinformatics* 2014;30(14):2068–2069; doi: 10.1093/BIOINFORMATICS/BTU153
 23. The Galaxy Community. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2022 Update. *Nucleic Acids Res* 2022;50(W1):W345–W351; doi: 10.1093/nar/gkac247
 24. Schwengers O, Jelonek L, Dieckmann MA, et al. Bakta: Rapid and standardized annotation of bacterial genomes via alignment-free sequence identification. *Microb Genom* 2021;7(11):000685; doi: 10.1099/MGEN.0.000685/CITE/REFWORKS
 25. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. *Genome Biol* 2019;20(1):1–13; doi: 10.1186/S13059-019-1891-0
 26. Yoon SH, Ha SM, Lim J, et al. A large-scale evaluation of algorithms to calculate average nucleotide identity. *Antonie Van Leeuwenhoek* 2017;110(10):1281–1286; doi: 10.1007/S10482-017-0844-4
 27. Meier-Kolthoff JP, Göker M. VICTOR: Genome-based phylogeny and classification of prokaryotic viruses. *Bioinformatics* 2017;33(21):3396–3404; doi: 10.1093/BIOINFORMATICS/BTX440
 28. Hockenberry AJ, Wilke CO. BACPHLIP: Predicting bacteriophage lifestyle from conserved protein domains. *PeerJ* 2021;9:e11396; doi: 10.7717/PEERJ.11396
 29. Krupovic M, Dutilh BE, Adriaenssens EM, et al. Taxonomy of prokaryotic viruses: Update from the ICTV bacterial and archaeal viruses subcommittee. *Arch Virol* 2016;161(4):1095–1099; doi: 10.1007/S00705-015-2728-0
 30. Townsend EM, Kelly L, Gannon L, et al. Isolation and characterization of *Klebsiella* phages for phage therapy. *Phage (New Rochelle)* 2021;2(1):26; doi: 10.1089/PHAGE.2020.0046
 31. Doub JB. Risk of bacteriophage therapeutics to transfer genetic material and contain contaminants beyond endotoxins with clinically relevant mitigation strategies. *Infect Drug Resist* 2021;14:5629; doi: 10.2147/IDR.S341265
 32. Venturini C, Ben Zakour NL, Bowring B, et al. Fine capsule variation affects bacteriophage susceptibility in *Klebsiella pneumoniae* ST258. *FASEB J* 2020;34(8):10801–10817; doi: 10.1096/fj.201902735R
 33. Martins W, Cino J, Li M, et al. Lytic bacteriophages against multidrug-resistant *Klebsiella pneumoniae*: Development of an effective phage-based approach to combat multidrug resistance. 2021;1–47; doi: 10.21203/RS.3.RS-850585/V1
 34. Nazir A, Qi C, Shi N, et al. Characterization and genomic analysis of a novel drexlervirial bacteriophage IME268 with lytic activity against *Klebsiella pneumoniae*. *Infect Drug Resist* 2022;15:1533–1546; doi: 10.2147/IDR.S347110
 35. Sime-Ngando T. Environmental bacteriophages: Viruses of microbes in aquatic ecosystems. *Front Microbiol* 2014;5(JULY):355; doi: 10.3389/FMICB.2014.00355
 36. Kasman LM, Porter LD. Bacteriophages. In: Brenner's Encyclopedia of Genetics (Second Edition). 2021; pp. 280–283; doi: 10.1016/B978-0-12-374984-0.00131-5
 37. Clokie MRJ, Millard AD, Letarov AV, et al. Phages in nature. *Bacteriophage* 2011;1(1):31–45; doi: 10.4161/bact.1.1.14942
 38. Lawrence D, Baldrige MT, Handley SA. Phages and human health: More than idle hitchhikers. *Viruses* 2019;11(7):587; doi: 10.3390/V11070587
 39. Edham M, Al-Tae Firas, Al-Hammadi ATY. Inhibitory effect of bacteriophages isolated from sewage water in the City of Kirkuk on some types of human pathogenic bacteria. 2017. Available from: <https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/2416/2347> [Last accessed: October 2, 2022].
 40. Nepal R, Houtak G, Karki S, et al. Genomic characterization of three bacteriophages targeting multidrug resistant clinical isolates of *Escherichia*, *Klebsiella* and *Salmonella*. *Arch Microbiol* 2022;204(6):1–9; doi: 10.1007/S00203-022-02948-0
 41. Ilyas SZ, Tariq H, Basit A, et al. SGP-C: A Broad Host Range Temperate Bacteriophage; Against *Salmonella gallinarum*. *Front Microbiol* 2022;12:4042; doi: 10.3389/FMICB.2021.768931
 42. Kęsik-Szeloch A, Drulis-Kawa Z, Weber-Dąbrowska B, et al. Characterising the biology of novel lytic bacteriophages infecting multidrug resistant *Klebsiella pneumoniae*. *Virol J* 2013;10(1):1–12; doi: 10.1186/1743-422X-10-100
 43. Jamal M, Hussain T, Rajanna Das C, et al. Characterization of siphoviridae phage Z and studying its efficacy against multidrug-resistant *Klebsiella pneumoniae* planktonic cells and biofilm. *J Med Microbiol* 2015;64(4):454–462; doi: 10.1099/JMM.0.000040
 44. Zurabov F, Zhilenkov E. Characterization of four virulent *Klebsiella pneumoniae* bacteriophages, and evaluation of their potential use in complex phage preparation. *Virol J* 2021;18(1):1–20; doi: 10.1186/S12985-020-01485-W
 45. Kortright KE, Chan BK, Koff JL, et al. Phage therapy: A renewed approach to combat antibiotic-resistant bacteria. *Cell Host Microbe* 2019;25(2):219–232; doi: 10.1016/J.CHOM.2019.01.014
 46. Fang Q, Feng Y, McNally A, et al. Characterization of phage resistance and phages capable of intestinal decolonization of carbapenem-resistant *Klebsiella pneumoniae* in mice. *Commun Biol* 2022;5(1):1–14; doi: 10.1038/s42003-022-03001-y
 47. Han ML, Nang SC, Lin YW, et al. Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant *Klebsiella pneumoniae* by a bacteriophage-polymyxin combination. *Comput Struct Biotechnol J* 2022;20:485–495; doi: 10.1016/J.CSBJ.2021.12.039

48. Shao Y, Wang IN. Bacteriophage adsorption rate and optimal lysis time. *Genetics* 2008;180(1):471; doi: 10.1534/GENETICS.108.090100
49. Gallet R, Shao Y, Wang IN. High adsorption rate is detrimental to bacteriophage fitness in a biofilm-like environment. *BMC Evol Biol* 2009;9(1):1–12; doi: 10.1186/1471-2148-9-241
50. Dennehy JJ, Abedon ST. Adsorption: Phage acquisition of bacteria. In: *Bacteriophages*. (Harper DR, Abedon ST, Burrowes BH, et al. eds.) Springer: Cham; 2021; pp. 93–117; doi: 10.1007/978-3-319-41986-2_2
51. Song L, Yang X, Huang J, et al. Phage selective pressure reduces virulence of hypervirulent *Klebsiella pneumoniae* through mutation of the *wzc* gene. *Front Microbiol* 2021; 12:2904; doi: 10.3389/FMICB.2021.739319
52. Bonilla BE, Costa AR, van denBerg DF, et al. Genomic characterization of four novel bacteriophages infecting the clinical pathogen *Klebsiella pneumoniae*. *Oxford* 2021; 28(4):dsab013; doi: 10.1093/dnares/dsab013
53. Bull JJ, Gill JJ. The habits of highly effective phages: Population dynamics as a framework for identifying therapeutic phages. *Front Microbiol* 2014;5:618; doi: 10.3389/FMICB.2014.00618
54. Pan Y-J, Lin T-L, Chen C-C, et al. *Klebsiella* Phage Φ K64–1 encodes multiple depolymerases for multiple host capsular types. *J Virol* 2017;91(6):2457–2473; doi: 10.1128/JVI.02457-16
55. Edwards RA, McNair K, Faust K, et al. Computational approaches to predict bacteriophage-host relationships. *FEMS Microbiol Rev* 2016;40(2):258–272; doi: 10.1093/FEMSRE/FUV048
56. Ploss M, Kuhn A. Membrane insertion and assembly of epitope-tagged gp9 at the tip of the M13 phage. *BMC Microbiol* 2011;11:211; doi: 10.1186/1471-2180-11-211
57. Gorodnichev RB, Volozhantsev NV, Krasilnikova VM, et al. Novel *Klebsiella pneumoniae* K23-specific bacteriophages from different families: Similarity of depolymerases and their therapeutic potential. *Front Microbiol* 2021;12: 2223; doi: 10.3389/FMICB.2021.669618
58. Li X, Koç C, Kühner P, et al. An essential role for the baseplate protein Gp45 in phage adsorption to *Staphylococcus aureus*. *Sci Rep* 2016;6:26455; doi: 10.1038/SREP26455
59. Wang T, Lin H, Zhang L, et al. Expression and purification of recombinant lyase gp17 from the LSB-1 phage in *Escherichia coli*. *Viol Sin* 2015;30(1):69–72; doi: 10.1007/S12250-014-3527-6
60. Fokine A, Rossmann MG. Molecular architecture of tailed double-stranded DNA phages. *Bacteriophage* 2014;4(2): e28281; doi: 10.4161/bact.28281
61. Bailly-Bechet M, Vergassola M, Rocha E. Causes for the intriguing presence of tRNAs in phages. *Genome Res* 2007; 17(10):1486–1495; doi: 10.1101/GR.6649807
62. Maganha de Almeida Kumlien AC, Pérez-Vega C, González-Villalobos E, et al. Genome analysis of a new *Escherichia* phage vB_EcoM_C2–3 with lytic activity against multidrug-resistant *Escherichia coli*. *Virus Res* 2022;307:198623; doi: 10.1016/J.VIRUSRES.2021.198623
63. Yang JY, Fang W, Miranda-Sanchez F, et al. Degradation of host translational machinery drives tRNA acquisition in viruses. *Cell Syst* 2021;12(8):771.e5–779.e5; doi: 10.1016/J.CELS.2021.05.019
64. Delesalle VA, Tanke NT, Vill AC, et al. Testing hypotheses for the presence of tRNA genes in mycobacteriophage genomes. *Bacteriophage* 2016;6(3):e1219441; doi: 10.1080/21597081.2016.1219441
65. Nielsen TK, Carstens AB, Browne P, et al. The first characterized phage against a member of the ecologically important sphingomonads reveals high dissimilarity against all other known phages. *Sci Rep* 2017;7(1):1–10; doi: 10.1038/s41598-017-13911-1
66. Morgado S, Vicente AC. Global In-silico scenario of tRNA genes and their organization in virus genomes. *Viruses* 2019;11(2):180; doi: 10.3390/V11020180

Address correspondence to:

Jorge Aníbal Reyes, PhD

Facultad de Ciencias Químicas

Departamento de Microbiología

Universidad Central del Ecuador (UCE)

Ciudadela Universitaria Avenida América

Quito 170129, Pichincha

Ecuador

E-mail: jareyesc@uce.edu.ec;

jorge.reyesc@iess.gob.ec; jorgereyes83@gmail.com